

19. A method for reducing the CYP2C9 enzyme inhibitory activity of a compound, comprising the steps of identifying the compound as an inhibitor of CYP2C9 in an assay according to claim 10; and thereafter producing a chemically modified version of the test compound in which the functionality suspected to be responsible for CYP2C9 inhibition is eliminated or changed.


20. A novel compound produced according to the method of claim 19.--.

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP99/07416 into the U.S. national phase of prosecution. Claims 1-9 have been deleted and new claims 10-20 have been added to replace the original claims, and to place the claims into proper U.S. format.

In view of the foregoing, favorable consideration of claims 10-20 are respectfully solicited.

Respectfully submitted,



Nora Stein-Fernandez
Attorney for Applicants
Registration No. 36,689

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090

n:\nsf\patapps\p32158\preamend for national.doc

Int'l. App. No: PCT/EP99/07416
Int'l. File Date: 4 October 1999

09/806877
C02 Rec'd PCT/PTO 05 APR 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

This amendment deleted all of the previous claims and added a new set.
As such, a marked up version of previous claims are not required.